THNR - ETF AI Analysis
Top Page
Amplify Weight Loss Drug & Treatment ETF (THNR)
Rating:61Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong short-term gains over the last one and three months, suggesting positive recent momentum in its holdings.
Leading Health Care Companies
Several top holdings, including major drug makers and biotechs, have delivered strong year-to-date performance, helping support the fund’s returns.
Global Exposure Within a Focused Theme
While the fund is mainly invested in U.S. companies, it also holds meaningful positions in Hong Kong and Japan, adding some international diversification to its weight-loss treatment focus.
Negative Factors
High Sector Concentration
With almost all assets in health care, the ETF is heavily exposed to risks specific to drug development, regulation, and sentiment toward weight-loss treatments.
Mixed Performance Among Top Holdings
A few large positions, such as Novo Nordisk and Regeneron, have shown weak year-to-date performance, which can drag on overall fund results.
Above-Average Expense Ratio
The fund’s expense ratio is relatively high for an ETF, meaning more of investors’ returns are used to cover fees.
THNR vs. SPDR S&P 500 ETF (SPY)
AUM5.42M
RegionDeveloped Markets
Expense Ratio0.59%
Beta0.64
IssuerAmplify
Inception DateMay 21, 2024
Dividend Yield1.53%
Asset ClassEquity
Index TrackedVettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,541
30 Day Avg. Volume2,076
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
33.54Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
THNR Summary
The Amplify Weight Loss Drug & Treatment ETF (THNR) is a fund that follows the VettaFi Weight Loss Drug & Treatment Index and focuses on health care companies working on weight loss drugs and related treatments. It mainly holds pharmaceutical and biotech firms, including well-known names like Novo Nordisk and Eli Lilly, which make popular weight loss and diabetes medications. Someone might invest in this ETF to seek growth from the rising demand for obesity and weight management treatments and to get diversified exposure to many companies in this niche. A key risk is that it is heavily concentrated in health care and can rise or fall sharply with news about drug approvals, regulations, or medical breakthroughs.
How much will it cost me?The Amplify Weight Loss Drug & Treatment ETF (THNR) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed and focuses on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise required to select investments.
What would affect this ETF?The Amplify Weight Loss Drug & Treatment ETF (THNR) could benefit from growing global awareness of obesity-related health issues and increased demand for innovative weight loss treatments, especially as its top holdings include major pharmaceutical companies like Eli Lilly and Novo Nordisk, which are leaders in this space. However, the ETF may face challenges from regulatory hurdles, competition in drug development, or economic downturns that could reduce consumer spending on health care solutions. Additionally, its heavy reliance on the health care sector makes it vulnerable to sector-specific risks, such as changes in government policies or patent expirations.
THNR Top 10 Holdings
THNR is essentially a bet on the global weight-loss and obesity-treatment boom, with a heavy tilt toward big pharma and biotech. Novo Nordisk and Eli Lilly are still the headline acts, but their shares have been losing a bit of steam lately, so they’re not pulling the fund as hard as before. Instead, rising names like Regeneron, Merck, and Amgen are doing more of the heavy lifting. With most exposure in developed markets and a tight focus on health care innovators, this ETF is concentrated but thematically very clear.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novo Nordisk | 9.17% | $497.24K | $205.87B | -15.62% | 73 Outperform | |
| Eli Lilly & Co | 8.49% | $460.36K | $1.08T | 58.05% | 72 Outperform | |
| Regeneron | 6.25% | $339.07K | $85.22B | 44.36% | 78 Outperform | |
| Innovent Biologics | 6.15% | $333.71K | HK$178.57B | -3.96% | 61 Neutral | |
| CSPC Pharmaceutical Group | 5.88% | $318.69K | HK$111.41B | -12.94% | 63 Neutral | |
| Amgen | 5.68% | $308.22K | $236.38B | 54.15% | 77 Outperform | |
| Merck & Company | 5.55% | $301.18K | $370.89B | 77.46% | 80 Outperform | |
| Scholar Rock Holding | 5.51% | $298.72K | $6.74B | 76.15% | 50 Neutral | |
| Arrowhead Pharmaceuticals | 5.11% | $277.37K | $12.20B | 196.96% | 57 Neutral | |
| AbbVie | 5.09% | $276.34K | $453.19B | 20.65% | 66 Neutral |
THNR Technical Analysis
Positive
―
Price Trends
26.31
Positive
25.40
Positive
25.35
Positive
Market Momentum
0.27
Positive
54.19
Neutral
34.83
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For THNR, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.99, equal to the 50-day MA of 26.31, and equal to the 200-day MA of 25.35, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 54.19 is Neutral, neither overbought nor oversold. The STOCH value of 34.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for THNR.
THNR Peer Comparison
Comparison Results
Performance Comparison
THNR
Amplify Weight Loss Drug & Treatment ETF
27.01
4.01
17.43%
AGNG
Global X Aging Population ETF
―
―
―
FDIQ
Invesco Bloomberg Financial Data Providers ETF
―
―
―
WISE
Themes Generative Artificial Intelligence ETF
―
―
―
IVEP
Dan IVES Wedbush AI Power & Infrastructure ETF
―
―
―
FOWF
Pacer Solactive Whitney Future of Warfare ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents